Bausch Health announces publication of pivotal phase 3 efficacy and safety data on ALTRENO
Bausch Health announced the Journal of Drugs in Dermatology has published results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining efficacy and safety of ALTRENOTM (tretinoin) Lotion, 0.05% for topical treatment of acne vulgaris. October 11, 2018
